

iTrack™
ADVANCE


Nova Eye Medical Limited (ASX:EYE)
Stent-Free, Tissue-Preserving, Repeatable
Glaucoma Surgery

November 2025

Disclaimer





This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medical (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.



1. Drainage canal becomes blocked; too much fluid stays in the eye and IOP rises.

2. High IOP damages optic nerve, leading to blindness.



The Interventional Glaucoma Market Size & Our Position



84M

People with
open - angle cases



Device market **US\$944M**
(2025) → **US\$1.6B**
(2030), CAGR 10.6%



Pharma spend **US\$4.3B** –
but very poor compliance
and long term not good for
QOL

U.S. market is 53%
of global revenue,
growing 10% p.a.

Cataract link:
32M procedures yearly;
1 in 5 patients also have
glaucoma – shared
access point

Nova Eye **stent free
tissue sparing approach**
makes it a fast-growing
interventional glaucoma
company in the U.S. (24%
LTM to 30 Sep 2025)

Interventional glaucoma means active surgical engagement to change disease trajectory

Highlighting Competitive Position in the U.S.




iTrack™ Advance: FDA-cleared 2023; no implant, no foreign material

- Complements cataract surgery; preserves tissue
- U.S. reimbursement (CMS 2026): surgeon US\$542 + facility ~US\$2,231
- ~15,000 U.S. procedures per annum, ~3.5% MIGS share and rising

Why Do Surgeons Choose iTrack™ Advance?

- **Procedure:** Canaloplasty – restores natural drainage (“angioplasty of the eye”).
- **FDA approved** to treat glaucoma; targets the full natural outflow pathway (TM, Schlemm’s Canal, collector channels).
- **Implant-free and tissue-preserving** – no foreign material left in the eye.
- **Single-pass 360° treatment**, delivering even viscodilation around the canal.
- **Compared with other MIGS devices:**
 - KDB and OMNI involve cutting or combining procedures.
 - iStent and Hydrus require implants.
 - iTrack™ uniquely maintains natural anatomy and can be repeated.



Source: Company calculation based on MarketScope 2024 Glaucoma Surgical Device Market Report.

USA Commercial Infrastructure is valuable



EXECUTE

Recruit and train sales representatives to take the message to surgeons. Achieving c\$1.4 million RPR at high margin... Number of reps is a function of Company strategy to provide BOTH growth and EBITDA positive. (currently FTE 12)



Sales management: sales rep recruitment and motivation, territory management for growth, supervision and messaging



Consistent surgical technique: Clinical trainers and participation in teaching institutions

EXCITE THE MARKET

Brand awareness, KOL support, product messaging and positioning & promotion

STRONG FOUNDATION

Medicare reimbursement & pricing
 Cat 1 code in USA
 Profitable for all parties

Clinical data & regulatory clearances
 FDA approval
 Significant clinical evidence

Product that is safe & efficacious with unique MOA
 175,000 procedures


Inventory, manufacturing, quality, supply chain, customer service, DIFOT
 Capacity 100,000 units, current production 25,000 units

OUS Sales Channels and China Opportunity



**Like in USA, Direct sales
Germany = high margin
and control**

**Significant opportunity
in China following recent
product approval**



In Germany, we have a small team that trains and sells directly to surgeons and manages and supports distributor partners in Europe.

We are highly selective in our commercial investments in Europe (and in the rest of the world) to ensure we achieve our corporate objectives.

In China, we have a distribution partner that has been selling our original iTrack™. The iTrack™ Advance, approved in September, provides a significant growth opportunity.

The number of patients having cataract surgery who have been diagnosed with concurrent glaucoma is expected to increase by 5 times to 4 million per year, and interventional glaucoma therapies will rise.

In the USA, approximately 1 million patients with glaucoma undergo cataract surgery each year, so we expect that, in the long term, the Chinese market will be 4x larger than the USA.

Sales Outlook and Recap



- ✓ **iTrack™ Advance = angioplasty of the eye**
– natural flow restored, repeatable

- ✓ **Single-use device drives recurring revenue**

- ✓ **Record October 2025 revenue**

- ✓ **FY26 guidance: US\$21–24M sales, breakeven H2 FY26**

- ✓ **China approval for iTrack™ Advance received adds growth option**

Focus
Increase
U.S. procedures
quarter-on-quarter
and deliver
sustainable
profitability.

A large, light teal circular callout bubble with a darker teal border, containing the text 'Focus Increase U.S. procedures quarter-on-quarter and deliver sustainable profitability.'



Tom Spurling

Managing Director

+61 8 8360193

tspurling@nova-eye.com

Mark Flynn

Investor Relations

+61 416 068 733

mflynn@nova-eye.com